United Community Banks (NYSE: UCB) reported in-line earnings for the fourth quarter on Wednesday. The company posted ...

United Community Banks, Inc. is rated a Buy due to solid Q4, robust loan growth and strong key metrics. Learn more about UCB ...

United Community Banks (UCB) has drawn fresh attention after recent trading that left the stock near $33.39, prompting investors to revisit its performance, valuation signals and the bank’s underlying ...

Regional banking company United Community Banks (NYSE:UCB) reported Q4 CY2025 results , with sales up 10.5% year on year to ...

Q4 2025 Earnings Call Transcript January 14, 2026 United Community Banks, Inc. misses on earnings expectations. Reported EPS is $0.71 EPS, expectations were $0.73. Operator: Good morning, and welcome ...

United Community Banks Inc (UCB) reports robust financial performance with significant revenue growth and strategic initiatives to enhance shareholder value.

The Food and Drug Administration declined to approve UCB’s Biologics License Application for bimekizumab, its treatment for adults with moderate to severe plaque psoriasis. The Belgian biopharma ...

After a manufacturing-related complete response letter held up the U.S. launch of UCB’s psoriasis med bimekizumab last May, the FDA has officially closed out its inspection of the company's plant in ...

UCB (EBR:UCB) * GSK to acquire from UCB commercial operations and product distribution rights for selected markets in the Far-East, Middle-East, Latin America and Africa * UCB receives EUR 515 million ...